For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
43
views
11
references
 Top references
cited by
4
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
1 collections
    0
    shares
      12
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Severe hypotony and filtering bleb leak after intravitreal injection of ranibizumab

      case-report

      Read this article at

      ScienceOpenPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We report a case of a patient with age-related macular degeneration, who had undergone trabeculectomy nine years earlier, and developed severe hypotony and bleb leak after treatment with intravitreal injections of ranibizumab. Although the incident is rare, in patients with longstanding filtering blebs, who need treatment with antivascular endothelial growth factors, close follow-up may be advocated, since the occurrence of bleb rupture could lead to permanent vision loss.

          Most cited references11

          • Record: found
          • Abstract: not found
          • Article: not found

          Trabeculectomy. Preliminary report of a new method.

          J Cairns (1968)
          Article 0 comments Cited 150 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies.

            Jayakrishna Ambati, Balamurali Ambati, Sonia H Yoo … (2015)
            Age-related macular degeneration is the principal cause of registered legal blindness among those aged over 65 in the United States, western Europe, Australia, and Japan. Despite intensive research, the precise etiology of molecular events that underlie age-related macular degeneration is poorly understood. However, investigations on parallel fronts are addressing this prevalent public health problem. Sophisticated biochemical and biophysical techniques have refined our understanding of the pathobiology of drusen, geographic atrophy, and retinal pigment epithelial detachments. Epidemiological identification of risk factors has facilitated an intelligent search for underlying mechanisms and fueled clinical investigation of behavior modification. Gene searches have not only brought us to the cusp of identifying the culpable gene loci in age-related macular degeneration, but also localized genes responsible for other macular dystrophies. Recent and ongoing investigations, often cued by tumor biology, have revealed an important role for various growth factors, particularly in the neovascular form of the condition. Transgenic and knockout studies have provided important mechanistic insights into the development of choroidal neovascularization, the principal cause of vision loss in age-related macular degeneration. This in turn has culminated in preclinical and clinical trials of directed molecular interventions.
            Article 0 comments Cited 134 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.

              David Fei, Jeriza Rusit, Jacques Gaudreault … (2005)
              Ranibizumab (rhuFab V2; Lucentis, Genentech, South San Francisco, CA) is a humanized monoclonal antibody fragment designed to bind all forms of VEGF, thereby blocking vessel permeability and angiogenesis in neovascular age-related macular degeneration. This study evaluated the pharmacokinetic (PK) and serum bioavailability of ranibizumab after a single intravitreal (ITV) or intravenous (IV) dose in cynomolgus monkeys. Monkeys received ranibizumab as either a bilateral ITV dose (500 or 2000 microg/eye; n = 6/group) or a single IV dose (1000 or 4000 microg/animal; n = 4/group). After ITV administration, ranibizumab concentrations were measured in several ocular compartments and in serum for 10 days and, after IV administration, for 48 hours. Pharmacokinetic parameters were estimated by compartmental and noncompartmental methods. Ranibizumab cleared in parallel from all ocular compartments, with a terminal half-life of approximately 3 days. It distributed rapidly to the retina (6-24 hours), and concentrations were approximately one third that in the vitreous. After ITV injection, bioavailability (F) was 50% to 60%. Serum concentrations were very low, reflecting wider distribution and faster clearance when ranibizumab reached the serum. After IV administration, the terminal half-life was approximately 0.5 day. This study demonstrates that ranibizumab has a PK profile that is favorable for its clinical use in treating neovascular AMD by monthly ITV injection.
              Article 0 comments Cited 104 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Ther Clin Risk Manag
                Journal ID (publisher-id): Therapeutics and Clinical Risk Management
                Title: Therapeutics and Clinical Risk Management
                Publisher: Dove Medical Press
                ISSN (Print): 1176-6336
                ISSN (Electronic): 1178-203X
                Publication date Collection: 2009
                Publication date (Print): 2009
                Publication date (Electronic): 26 March 2009
                Volume: 5
                Pages: 17-19
                Affiliations
                “G.Gennimatas” Hospital of Athens, NHS, Athens, Greece
                Author notes
                Correspondence: Ilias Georgalas, Consultant Vitreoretinal Surgeon, 59 Chrysanthemon str., P. Pshychico, 15452 Athens, Greece, Tel +302107768374, Fax +302107768374, Email igeorgalas@ 123456yahoo.com
                Article
                Publisher ID: tcrm-5-0017
                PMC ID: 2697510
                PubMed ID: 19436608
                SO-VID: fb78e13e-a6fa-4146-8e85-88e33b90178e
                Copyright © © 2009 Georgalas et al, publisher and licensee Dove Medical Press Ltd.
                License:

                This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

                History
                Categories
                Subject: Case Report

                ScienceOpen disciplines: Medicine
                Keywords: trabeculectomy,ranibizumab,age-related macular degeneration
                Data availability:
                ScienceOpen disciplines: Medicine
                Keywords: trabeculectomy, ranibizumab, age-related macular degeneration

                Comments

                Comment on this article

                Similar content12

                See all similar

                Cited by4

                See all cited by

                Most referenced authors158

                See all reference authors